Takeda gains FDA OK for potential insomnia blockbuster

Japan's Takeda has won FDA approval for Rozerem, a new sleep drug that will be the first prescription drug for insomnia not classified as a controlled substance. The approval is a coup for Takeda, positioning it to enter the fast-growing sleep drug category behind Sepracor's Lunesta. Neurocrine Bioscience and Merck are also each developing a new sleep drug, which they hope will compete for a growing, multibillion-dollar market that for years has been dominated by Ambien. A controlled-release form of Ambien is also in the works.

- read this report from Japan Today for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.